Compare Eli Lilly And Co (LLY) vs Occidental Petroleum Corporation (OXY) Price & Performance

Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.

Occidental Petroleum (OXY) trades at $60.52, up 3.97% in the last session, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.40 surpassing the $1.83 expectation. Financial health is supported by a strong net income margin of 30.32% and an ROE of 21.46%, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Analyst consensus is a Buy with a $71.40 price target, and a dividend of $0.28 is scheduled for payment in October 2026.

OXY presents a positive outlook driven by earnings beats, debt reduction efforts, and analyst optimism, but faces risks from volatile oil prices and declining revenue trends. Investment appeal hinges on execution of cash flow targets and oil market stability, with current valuation metrics like a P/E of 17.78 appearing reasonable relative to growth prospects.